MEDBOTX™
MEDBOTX™ for Personalized Medicines
PharmaTher believes healthcare is moving toward greater personalization, including patient-specific dosing, alternative delivery formats, combination therapies, improved adherence and localized manufacturing. These trends are particularly relevant in settings where conventional mass manufacturing may not address the needs of specific patients, prescribers or clinical workflows.
MEDBOTX™ is being designed as a point-of-care and small-batch manufacturing platform that may support personalized dose forms, including polypills, tablets, oral films, gels, suppositories, chews, patches, osmotic-pump formats, and other advanced drug delivery formats. PharmaTher’s initial commercial focus is expected to include personalized medicines, regulated peptide opportunities, compounded pharmaceuticals, partner-facing formulation and development services, and PharmaTher internal product developments.
PharmaTher believes healthcare is moving toward greater personalization, including patient-specific dosing, alternative delivery formats, combination therapies, improved adherence and localized manufacturing. These trends are particularly relevant in settings where conventional mass manufacturing may not address the needs of specific patients, prescribers or clinical workflows.
MEDBOTX™ is being designed as a point-of-care and small-batch manufacturing platform that may support personalized dose forms, including polypills, tablets, oral films, gels, suppositories, chews, patches, osmotic-pump formats, and other advanced drug delivery formats. PharmaTher’s initial commercial focus is expected to include personalized medicines, regulated peptide opportunities, compounded pharmaceuticals, partner-facing formulation and development services, and PharmaTher internal product developments.
© COPYRIGHT 2026. PharmaTher Holdings Ltd. ALL RIGHTS RESERVED.
"The product candidates described on this website are investigational and have not been approved by the U.S. Food and Drug Administration (FDA) or any other regulatory authority. Safety and efficacy have not been established."